Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Obesity

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

Benzinga

Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over the drugmaker Metsera

The Independent UK

Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Scientists discover five new genes which increase obesity risk

Scientists have identified 13 genes that could increase a person’s risk of developing obesity

The Independent UK

The US obesity rate is declining thanks to weight loss drugs, survey finds

There are now 7.6 million fewer American adults living with obesity

The Independent UK

Viking Therapeutics: High Risk, High Reward Play

Viking Therapeutics stock surges as Phase 3 trials progress for its GLP-1 obesity drug, with analysts seeing major upside potential

MarketBeat

Gender lens needed to examine weight management

Weight management for women can be impacted by a variety of biological and emotional factors, with experts saying a gender-focused approach is needed.

AAP

Read news from The Economist, FT, and more,
with one subscription

Ventyx Stock Is Rallying Thursday: What's Driving The Surge?

Ventyx Biosciences Inc (NASDAQ:VTYX) shares are surging Thursday after the company announced positive Phase 2 study results for VTX3232 in patients with obesity and cardiovascular risk factors.

Benzinga

Why Ventyx (VTYX) Shares Soared 86.5% After Hours?

Ventyx Biosciences Inc. (NASDAQ:VTYX) jumped 86.53% to $7.20 in after-hours trading on Wednesday after the company reported positive Phase 2 trial results for its obesity and cardiovascular risk drug candidate, VTX3232.

Benzinga

Anti-obesity drugs have heart health benefits beyond weight loss, study finds

The findings suggest weight loss drugs independently affect heart health risks, researchers said.

Euronews

Anti-obesity jabs ‘reduce heart attack risk’ regardless of weight lost – study

The benefits extend beyond the loss of weight alone.

The Independent UK

Trump’s approach to lowering drug costs is raising questions - Roll Call

Several drug pricing experts say without key details, it’s hard to call the individual pharma deals a win for the Trump administration.

Roll Call

Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?

On Tuesday, Terns Pharmaceuticals Inc. (NASDAQ:TERN) shared topline 12-week results from its FALCON Phase 2 trial of TERN-601.

Benzinga

Global study warns of surging obesity-related cancers among older adults

Scientists say accumulation of fat can induce inflammation, alter hormone levels, disrupt cell metabolism, and foster a pro-carcinogenic environment

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Euronews

Thyroid, breast, colorectal, kidney, and endometrial cancer diagnoses are surging worldwide, with colorectal cancer increasing fastest in people under 50.

The Guardian - UK

Chemical linked to low sperm count, obesity and cancer found in dummies, tests find

BPA, a synthetic chemical used in production of plastics, found in baby products made by three big European brands

Euronews

Nearly 70% of US adults considered obese under proposed new definition, study finds

The new approach would label someone as being obese if they have a BMI over 40 or other signs of weight-related health problems.

The Independent UK

Dramatic increase in American adults who meet a new definition of obesity: ‘This is astounding’

Obesity linked to more than 40 diseases including certain cancers

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Obesity remains high in the US, but more states are showing progress, a new report finds

For the first time in more than a decade, the number of states with rates of obesity of 35% or more has dropped

Axios

Some good news on obesity — but with major caveats

The number of states with an extremely high obesity rate dropped but remains historically high.

MarketBeat

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead

Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments

The Guardian - UK

Almost 70% of US adults would be deemed obese based on new definition, study finds

Medical experts have called for new way to more accurately measure obesity, although definition has yet to be adopted

Benzinga

Twin Health, Peloton Team Up To Tackle Diabetes, Obesity With AI And Fitness

Twin Health, a pioneer in AI-driven digital twin technology for metabolic health, announced on Tuesday that it has partnered with Peloton Interactive, Inc. (NASDAQ:PTON) to enhance its wellness platform.

The Conversation

BMI shouldn’t be the only way to assess who can access weight-loss drugs

Around one in three Australian adults (32%) has a body-mass index (BMI) of 30 or above. A further 34% has a BMI of 25 or above.

Benzinga

Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations

Bill Gates and the Pan American Health Organization (PAHO) are reportedly developing plans to expand access to popular weight-loss drugs such as Novo Nordisk A/S’ (NYSE:NVO) Wegovy and Eli Lilly and Co.’s (NYSE:LLY) Mounjaro in low- and middle-income countries.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.